Molecular therapy

In conclusion, several vector systems are available in the molecular therapy toolbox, each suited for specific applications. 

GIBBONS G H and DZAU V J (1996) Molecular therapies for vascular disease Science 111, 689-93. 

Ghosh, S., Parvez, M.K., Banerjee, K. et al. (2002) Baculovirus as mammalian cell expression vector for gene therapy an emerging strategy. Molecular Therapy The Journal of the American Society of Gene Therapy, 6(1), 5-11. 

Reichert, J. and Paquette, C. 2003. Therapeutic recombinant proteins trends in US approvals 1982-2002. Current Opinion in Molecular Therapy 5, 139-147. 

Sally-Ann Poulsen, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Queensland, Australia... 

Verma, I.M. 2002. Biopiraq Distrust Widens the Rich-Poor Divide. Molecular Therapy 5 no. 2 (2002) 95. 

A similar phenomenon has also been reported in B cells derived from chronic lymphoid leukemia (CLL) patients in which mFas is deficient or defective. Fresh de novo CLL cells, which express low levels of mFas, are resistant to agonistic anti-Fas mAb-mediated apoptosis, while CLL cells that acquire abundant mFas after short-term culture become sensitive (T4) to such induction of apoptosis. This flexibility in production of the isoforms is expected to provide a target for selective molecular therapy of tumors on the basis of manipulating decoy action of sFas. 

Caplen, N., Zheng, Z., Falgout, B. and Morgan, R. (2002) Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference. Molecular Therapy 6, 243. 

Department of Pediatrics, Division of Cell and Molecular Therapies, University of Florida, Box 100296, Gainesville, FL 32610-0296, USA... 

Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I., and Lage, H. (2008) Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDRl short hairpin RNA-encoding plasmid DNA. Molecular Therapy 16(1) 178—186. 

Howard, K.A., Rahbek, U.L., Liu, X., Damgaard, C.K., Glud, S.Z., Andersen,M.O., Hovgaard,M.B., Schmitz, A. etal. (2006) RNA interference invitro and in vivo using a novel chitosan/siRNA nanoparticle system. Molecular Therapy 14 476-484. 

Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE. Transport of phosphorothioate oligonucleotides in kidney implications for molecular therapy. Kidney Int 1995 47 1462-9. 

Designer molecular therapy. A tyrosine kinase inhibitor, imatinib, is specifically designed to block the dysregulated t5n"osine kinase hyperactivity produced by the Philadelphia chromosome that is specific for chronic granulocytic leukaemia clinical trials support its efficacy in this disease. 

Corresponding Author Andreas Hofmann—Structural Chemistry, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Brisbane Innovation Park, Don Young Road, Brisbane, Qld, 4111, Australia. Email a.hofmann griffith.edu.au... 

Navia BA, Rostasy K (2005) The AIDS dementia complex Clinical and basic neuroscience with implications for novel molecular therapies. Neurotox Res 8 3-24. 

A number of different pharmacological chaperones that correct folding states of mutant proteins and enable their trafficking to the proper locale would be excellent candidates for a new molecular therapy of human genetic disorders. It can be expected that orally administered pharmacological chaperones will become the standard treatment for broad genetic disorders with protein misfolding. 

---